Monoclonal antibody therapy for classical Hodgkin lymphoma (original) (raw)

Clinical advances in hematology & oncology : H&O, 2013

Antibody Therapy in Aggressive Lymphomas

Hematology, 2007

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma

Jeffrey White

Proceedings of the National Academy of Sciences of the United States of America, 2015

View PDFchevron_right

Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma

Georges NEWINGER

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015

View PDFchevron_right

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Christoph Driessen

Blood, 2003

View PDFchevron_right

Diagnostic, prognostic and therapeutic role of CD30 in lymphoma

Dr. Mutlu Vural

Expert Review of Hematology, 2016

View PDFchevron_right

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

G. Dastoli

Critical Reviews in Oncology/Hematology, 2001

View PDFchevron_right

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

Martin Dyer

Journal of Clinical Oncology, 2009

View PDFchevron_right

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation

Julia Cruz

Biology of Blood and Marrow Transplantation, 2002

View PDFchevron_right

Novel CD20 monoclonal antibodies for lymphoma therapy

Nikhil Mukhi

Journal of Hematology & Oncology, 2012

View PDFchevron_right

Progressive Intermediate-Grade Non-Hodgkin's Lymphoma After High-Dose Therapy and Autologous Peripheral Stem-Cell Transplantation: Changing the Natural History with Monoclonal Antibody Therapy

Malik Juweid

Clinical Lymphoma, 2000

View PDFchevron_right

A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Miroslav Ravic

Blood, 2015

View PDFchevron_right

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

Stephen Schuster

Bone Marrow Transplantation, 1999

View PDFchevron_right

Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas

Julia Rincon

Cancer Treatment Reviews, 2015

View PDFchevron_right

Targeted immunotherapy in Hodgkin lymphoma

Martin Hutchings

Blood, 2015

View PDFchevron_right

Lymphoma Immunotherapy: Current Status

Massimo Di Nicola

Frontiers in Immunology, 2015

View PDFchevron_right

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Katrin Reiners

Blood, 2015

View PDFchevron_right

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Eric Sievers

Journal of Clinical Oncology, 2012

View PDFchevron_right

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

Michael L Goris

Clinical cancer research : an official journal of the American Association for Cancer Research, 1996

View PDFchevron_right

CD22-directed monoclonal antibody therapy for lymphoma

Alessandra Cesano

Seminars in Oncology, 2003

View PDFchevron_right

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Eric Sievers

New England Journal of Medicine, 2010

View PDFchevron_right

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

V. Augusti, Federico Carbone

Clinical and Developmental Immunology, 2010

View PDFchevron_right

CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies

Ashleigh Allen

Archives of Pathology & Laboratory Medicine, 2022

View PDFchevron_right

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party

Giovanni Pisapia

British journal of haematology, 2018

View PDFchevron_right

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

Massimo Martino

Journal of Immunology Research, 2015

View PDFchevron_right

Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma

Franck Morschhauser

Current Oncology Reports, 2011

View PDFchevron_right

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

vincenzo pavone

The oncologist, 2015

View PDFchevron_right

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Monic Stuart

…, 2004

View PDFchevron_right

A review of monoclonal antibody therapies in lymphoma

Yveline Chew

Critical Reviews in Oncology/Hematology, 2016

View PDFchevron_right

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma

Rashid Abbasi

Haematologica, 2011

View PDFchevron_right

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma

Urte Gayko

Clinical cancer …, 2004

View PDFchevron_right

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sin-Ho Jung

Leukemia & Lymphoma, 2013

View PDFchevron_right

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Srikanth Ambati

Blood

View PDFchevron_right

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

Josée Zijlstra

Haematologica

View PDFchevron_right

Monoclonal antibody therapy for classical Hodgkin lymphoma (original) (raw)

Related papers